Status:
ENROLLING_BY_INVITATION
Clinical Study on Lymphaticovenous Anastomosis（LVA） for the Treatment of Alzheimer's Disease（AD）
Lead Sponsor:
Peking University Third Hospital
Conditions:
Alzheimer&Amp;#39;s Disease (AD)
Eligibility:
All Genders
50-85 years
Phase:
NA
Brief Summary
The goal of this clinical trial is to explore the safety and efficacy of Lymphaticovenous Anastomosis (LVA) for the Treatment of Alzheimer's Disease (AD). The main questions it aims to answer are: 1....
Eligibility Criteria
Inclusion
- Patients diagnosed with Alzheimer's Disease based on biomarkers, imaging, and clinical symptoms;
- Male or female aged 50-85 years (inclusive);
- At least one caregiver who can live with the patient for an extended period;
- No severe systemic diseases affecting the heart, liver, kidneys, etc.;
- Patients who voluntarily participate in clinical recruitment, accept the LVA surgical treatment plan, and sign the informed consent form.
Exclusion
- Poor overall health, unable to tolerate surgery;
- Preoperative anesthetic assessment indicates inability to tolerate general anesthesia;
- Presence of other neurological or psychiatric disorders;
- Severe bleeding tendency due to coagulopathy;
- Inability to comply with treatment and follow-up;
- Other conditions that preclude tolerance to surgery.
Key Trial Info
Start Date :
April 2 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2030
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06918145
Start Date
April 2 2025
End Date
March 1 2030
Last Update
April 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking university third hospital
Beijing, Beijing Municipality, China, 100191